Preeclampsia Market

Preeclampsia Market Forecast and Outlook 2025 to 2035

The global preeclampsia market is projected to grow from USD 1.36 billion in 2025 to approximately USD 3.18 billion by 2035, registering an absolute increase of USD 1.82 billion during the forecast period. This represents a total growth of 133.8%, with the market expected to expand at a CAGR of 8.9% between 2025 and 2035.

Quick Stats for Preeclampsia Market

• Preeclampsia Market Value (2025): USD 1.36 billion
• Preeclampsia Market Forecast Value (2035): USD 3.18 billion
• Preeclampsia Market Forecast CAGR: 8.9%
• Leading Test Type in Preeclampsia Market: Blood Tests (59.0%)
• Key Growth Regions in Preeclampsia Market: Asia Pacific, North America, and Europe
• Key Players in Preeclampsia Market: Roche, Revvity (PerkinElmer), Thermo Fisher Scientific, Trinity Biotech, Sera Prognostics, Siemens Healthineers, Bayer AG, Quidel Corp, Eurofins NTD Genetics, Labcorp, mProbe Inc.

Market expansion will be driven by increasing demand for early detection diagnostics, broader integration of preeclampsia testing into maternal health screening programs and growing clinical reliance on biomarker-based technologies for accurate and timely diagnosis. The continued emphasis on reducing maternal and fetal mortality, alongside healthcare modernization in emerging economies, will further support sustained market growth through the next decade.

Between 2025 and 2030, the preeclampsia market is projected to expand from USD 1.36 billion to USD 2.13 billion, an increase of USD 0.77 billion, accounting for approximately 42.3% of total decade-long growth. This phase will be defined by rising awareness of preeclampsia’s clinical burden and increasing adoption of early-stage diagnostic tests in prenatal care.

Hospitals and obstetric clinics are expanding screening capacities to include biochemical and biophysical testing parameters such as placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and uterine artery Doppler analysis. Growing access to these diagnostic systems in middle-income nations, supported by government-funded maternal health programs, is expected to improve early intervention outcomes and reduce pregnancy-related complications.

From 2030 to 2035, the market is forecast to grow from USD 2.13 billion to USD 3.18 billion, adding another USD 1.05 billion, which represents approximately 57.7% of the decade’s expansion. This phase will likely be characterized by technological advancements in diagnostic precision, integration of next-generation biomarker testing platforms, and development of point-of-care devices optimized for prenatal applications.

The introduction of multiplex assay systems and microfluidic diagnostic technologies will enable rapid, quantitative assessments of key biomarkers, enhancing both accessibility and accuracy of testing in primary care environments. Growing standardization of universal screening guidelines, especially in high-risk populations, will reinforce the clinical adoption of automated testing systems with improved sensitivity and predictive value.

Between 2020 and 2025, the global preeclampsia market experienced steady development as healthcare systems prioritized maternal health and pregnancy-related risk assessment. Increased recognition of preeclampsia as a leading cause of maternal morbidity and mortality spurred clinical investments in diagnostic innovation.

Research and development efforts during this period focused on validating biomarker panels and improving assay reliability for differentiating between early-onset and late-onset preeclampsia. These advancements established a foundation for the commercialization of next-generation diagnostic products and data-integrated screening solutions.

Ongoing research in proteomics, genomics, and metabolomics is expected to shape the future of preeclampsia diagnostics by enabling personalized risk prediction and longitudinal monitoring throughout pregnancy. Integration of artificial intelligence (AI) and data analytics into diagnostic workflows will further improve screening precision and assist clinicians in identifying at-risk patients before symptom onset.

Between 2020 and 2025, the preeclampsia market experienced steady expansion, driven by increasing recognition of early detection technologies' importance in maternal health operations and growing acceptance of advanced biomarker solutions in complex prenatal care processes.

The market developed as healthcare providers recognized the need for high-efficiency diagnostic systems to address patient care requirements and improve overall maternal health outcomes. Research and development activities have begun to emphasize the importance of advanced preeclampsia testing technologies in achieving better efficiency and quality in prenatal care processes.

Preeclampsia Market Key Takeaways

Metric	Value
Estimated Value in (2025E)	USD 1.36 billion
Forecast Value in (2035F)	USD 3.18 billion
Forecast CAGR (2025 to 2035)	8.9%

The preeclampsia market represents a critical component of maternal healthcare delivery systems worldwide, with blood tests emerging as the dominant testing methodology and universal screening programs driving primary adoption patterns. Diagnostic centers lead end-user demand, while rapid growth in emerging markets, particularly India and China, is reshaping the competitive landscape.

The market benefits from regulatory approvals of FDA-cleared biomarker diagnostics, expanding maternal health programs, and increasing awareness of early detection benefits in preventing pregnancy complications. Market dynamics are characterized by the convergence of technological advancement in biomarker testing, expanding healthcare infrastructure in developing regions, and strengthening clinical guidelines for preeclampsia screening.

The shift toward first-trimester screening protocols and the adoption of sFlt-1/PlGF ratio assays reflect the healthcare industry's emphasis on early risk stratification and preventive maternal care. Companies investing in rapid diagnostic platforms, point-of-care testing solutions, and comprehensive screening programs are positioning themselves to capture significant market share as maternal health initiatives expand globally.

Why is the Preeclampsia Market Growing?

Market expansion is being supported by the increasing demand for early detection diagnostic solutions and the corresponding need for high-efficiency testing systems in preeclampsia screening applications across global maternal healthcare and prenatal care operations. Modern healthcare providers are increasingly focused on advanced biomarker testing technologies that can improve diagnostic efficiency, reduce maternal mortality costs, and enhance pregnancy outcomes while meeting stringent clinical requirements.

The proven efficacy of preeclampsia screening services in various maternal health applications makes them an essential component of comprehensive prenatal care strategies and obstetric programs. The growing emphasis on maternal healthcare transformation and advanced diagnostic optimization is driving demand for ultra-efficient preeclampsia testing systems that meet stringent performance specifications and clinical requirements for screening applications.

Healthcare providers' preference for reliable, high-performance diagnostic systems that can ensure consistent patient outcomes is creating opportunities for innovative biomarker technologies and customized maternal health solutions. The rising influence of clinical guidelines and screening protocols is also contributing to increased adoption of premium-grade preeclampsia diagnostics across different healthcare applications and obstetric systems requiring advanced testing technology.

Opportunity Pathways - Preeclampsia Market

The preeclampsia market represents a specialized growth opportunity, expanding from USD 1.36 billion in 2025 to USD 3.18 billion by 2035 at a 8.9% CAGR. As healthcare providers prioritize diagnostic efficiency, clinical compliance, and maternal care performance in complex prenatal processes, preeclampsia testing systems have evolved from a specialized diagnostic technology to an essential component enabling screening delivery, risk stratification optimization, and multi-stage obstetric care production across maternal health operations and specialized prenatal applications.

The convergence of healthcare expansion, increasing screening adoption, specialized maternal health organization growth, and diagnostic requirements creates momentum in demand. High-efficiency formulations offering superior testing performance, cost-effective blood test systems balancing performance with economics, and specialized biomarker variants for critical applications will capture market premiums, while geographic expansion into high-growth Asian healthcare markets and emerging market penetration will drive volume leadership. Clinical emphasis on diagnostic quality and testing reliability provides structural support.

• Pathway A - Blood Tests Dominance: Leading with 59.0% market share, blood test applications drive primary demand through complex healthcare workflows requiring comprehensive diagnostic systems for maternal health screening delivery. Advanced formulations enabling improved testing efficiency, reduced screening times, and enhanced patient outcomes command premium pricing from healthcare providers requiring stringent performance specifications and clinical compliance. Expected revenue pool: USD 1,876.2-2,256.2 million.
• Pathway B - Universal Screening Leadership: Dominating with 40.0% market share through an optimal balance of performance and cost-effectiveness, universal screening serves most healthcare applications while meeting maternal health requirements. This application addresses both performance standards and economic considerations, making it the preferred choice for healthcare and prenatal care operations seeking reliable performance. Opportunity: USD 1,272.0-1,544.0 million.
• Pathway C - Asian Market Acceleration: China (9.8% CAGR) and India (10.2% CAGR) lead global growth through healthcare infrastructure expansion, maternal health capability development, and domestic preeclampsia testing demand. Strategic partnerships with local healthcare providers, clinical compliance expertise, and supply chain localization enable the expansion of diagnostic technology in major healthcare hubs. Geographic expansion upside: USD 950.0-1,400.0 million.
• Pathway D - Diagnostic Centers Premium Segment: Diagnostic centers serve specialized applications requiring exceptional performance specifications for critical maternal health testing processes. Diagnostic center formulations supporting sterile laboratory requirements, complex biomarker applications, and performance-sensitive processes command significant premiums from advanced healthcare organizations and specialized maternal health facilities. Revenue potential: USD 1,113.0-1,431.0 million.
• Pathway E - Advanced Testing & Biomarker Systems: Companies investing in sophisticated preeclampsia testing technologies, maternal health diagnostic systems, and automated screening processes gain competitive advantages through consistent system performance and testing quality reliability. Advanced capabilities enabling customized specifications and rapid deployment capture premium healthcare partnerships. Technology premium: USD 850.0-1,250.0 million.
• Pathway F - Supply Chain Optimization & Reliability: Specialized distribution networks, strategic inventory management, and reliable supply chain systems create competitive differentiation in healthcare markets requiring consistent preeclampsia diagnostic availability. Companies offering guaranteed supply security, technical support, and clinical documentation gain preferred supplier status with compliance-focused healthcare providers. Supply chain value: USD 680.0-1,020.0 million.
• Pathway G - Emerging Applications & Market Development: Beyond traditional blood testing, preeclampsia diagnostics in rapid point-of-care testing, molecular screening, and specialized delivery systems represent growth opportunities. Companies developing new applications, supporting R&D initiatives, and expanding into adjacent maternal healthcare markets capture incremental demand while diversifying revenue streams. Emerging opportunity: USD 540.0-850.0 million.

Segmental Analysis

The market is segmented by test type, application, end use, and region. By test type, the market is divided into blood tests and urinalysis. By application, the market is categorized into universal screening, targeted testing, and monitoring & recurrence.

By end use, the market is divided into diagnostic centers, hospitals, specialty clinics, and others. Regionally, the market is divided into Asia Pacific, North America, Europe, Latin America, Middle East & Africa.

Which Test Type Segment Dominates in the Global Preeclampsia Market?

The blood tests segment is projected to account for 59.0% of the preeclampsia market in 2025, reaffirming its position as the category's dominant test type. Healthcare providers increasingly recognize the optimal balance of performance and cost-effectiveness offered by blood tests for most maternal health applications, particularly in screening delivery and prenatal care processes. This test type addresses both performance requirements and economic considerations while providing reliable diagnostics across diverse healthcare applications.

Within the blood tests category, sFlt-1/PlGF ratio assays represent 31.0% of the segment, demonstrating their critical role in early risk stratification and clinical decision-making. This test type forms the foundation of most clinical protocols for preeclampsia screening applications, as it represents the most widely accepted and commercially viable level of biomarker testing technology in the industry.

Performance control standards and extensive clinical validation continue to strengthen confidence in blood test formulations among healthcare and prenatal care providers. With increasing recognition of the cost-performance optimization requirements in maternal health diagnostics, blood test systems align both operational efficiency and patient care goals, making them the central growth driver of comprehensive prenatal care strategies.

By Application, Which Category is the Dominant One in the Preeclampsia Market?

Universal screening is projected to represent 40.0% of preeclampsia testing demand in 2025, underscoring its role as the primary application segment driving market adoption and growth. Healthcare providers recognize that universal screening requirements, including comprehensive prenatal testing processes, first-trimester detection needs, and multi-stage maternal health systems, often require advanced preeclampsia diagnostics that standard medical technologies cannot adequately provide. Universal screening offers enhanced diagnostic efficiency and clinical compliance in maternal healthcare applications.

First-trimester screening, accounting for 22.0% of the universal screening segment, represents the most proactive approach to preeclampsia risk assessment, enabling early intervention strategies that can significantly improve pregnancy outcomes. The segment is supported by the growing nature of universal screening adoption, requiring sophisticated diagnostic systems, and the increasing recognition that advanced preeclampsia testing technologies can improve healthcare performance and maternal health outcomes.

Healthcare providers are increasingly adopting evidence-based clinical guidelines that recommend specific preeclampsia screening services for optimal prenatal care outcomes. As understanding of maternal health complexity advances and healthcare requirements become more stringent, preeclampsia diagnostics will continue to play a crucial role in comprehensive obstetric strategies within the universal screening market.

Why are Diagnostic Centers the Dominant End-Users of Preeclampsia Testing?

Diagnostic centers are projected to represent 35.0% of preeclampsia testing demand in 2025, establishing their position as the leading end-user segment driving market adoption. Healthcare providers recognize that diagnostic center requirements, including specialized laboratory processes, advanced biomarker testing capabilities, and high-volume screening operations, require sophisticated preeclampsia diagnostics that can deliver consistent performance.

Urban labs, representing 18.0% of the diagnostic centers segment, demonstrate the concentration of testing capabilities in metropolitan healthcare infrastructure where access to advanced technologies and specialized expertise is most readily available. The segment is supported by the professional laboratory environment, state-of-the-art testing equipment, and the increasing recognition that diagnostic centers provide optimal conditions for complex biomarker analysis and quality control procedures.

The centralized nature of diagnostic centers enables economies of scale, standardized testing protocols, and efficient sample processing that are essential for high-volume maternal health screening programs. As maternal healthcare initiatives expand and screening coverage increases, diagnostic centers will continue to play a crucial role in delivering accurate and timely preeclampsia diagnostics across diverse patient populations and geographic regions.

What are the Drivers, Restraints, and Key Trends of the Preeclampsia Market?

The preeclampsia market is advancing steadily due to increasing recognition of early detection technologies' importance and growing demand for high-efficiency diagnostic systems across the maternal healthcare and prenatal care sectors.

The market faces challenges, including complex regulatory approval processes, potential for testing accuracy variations during implementation and validation, and concerns about supply chain consistency for specialized biomarker reagents. Innovation in diagnostic technologies and customized maternal health protocols continues to influence product development and market expansion patterns.

Expansion of Maternal Health Facilities and Biomarker Testing Technologies

The growing adoption of advanced maternal healthcare facilities is enabling the development of more sophisticated preeclampsia diagnostic and performance control systems that can meet stringent clinical requirements.

Specialized maternal health facilities offer comprehensive preeclampsia screening services, including advanced biomarker testing and risk stratification processes that are particularly important for achieving high-efficiency requirements in prenatal care applications.

Advanced diagnostic channels provide access to premium services that can optimize healthcare performance and reduce maternal mortality costs while maintaining cost-effectiveness for large-scale screening operations.

Integration of Digital Healthcare Systems and Laboratory Management Systems

Modern healthcare organizations are incorporating digital technologies such as real-time diagnostic monitoring, automated testing systems, and supply chain integration to enhance preeclampsia screening and distribution processes.

These technologies improve testing performance, enable continuous quality monitoring, and provide better coordination between providers and patients throughout the prenatal care cycle.

Advanced digital platforms also enable customized performance specifications and early identification of potential testing deviations or supply disruptions, supporting reliable maternal healthcare delivery production.

Regulatory Approvals and Clinical Guidelines Integration

Recent FDA clearances for sFlt-1/PlGF ratio assays and NICE-endorsed PlGF testing protocols are strengthening the evidence base for preeclampsia screening adoption across healthcare systems. Trinity Biotech's 2025 commercial launch of the FDA-cleared PreClara Ratio test with Thermo Fisher represents a significant milestone in expanding access to validated biomarker diagnostics in US hospitals.

Roche's Elecsys sFlt-1/PlGF ratio receiving FDA 510(k) clearance for preeclampsia risk stratification further validates the clinical utility of biomarker-based screening approaches. These regulatory approvals provide clinical confidence and reimbursement pathways necessary for widespread adoption in maternal health programs.

Analysis of the Preeclampsia Market by Key Countries

Country	CAGR (2025-2035)
India	10.2%
China	9.8%
USA	8.9%
Germany	8.4%
UK	8.1%
Japan	7.8%
Brazil	7.2%

The preeclampsia market is experiencing varied growth globally, with India leading at a 10.2% CAGR through 2035, driven by government-led maternal screening rollouts, low-cost biomarker adoption, and expanding healthcare infrastructure development. China follows at 9.8%, supported by regulatory approval of rapid urine tests, hospital digitization initiatives, and growing recognition of maternal health technology importance.

The USA records 8.9% growth, with FDA-cleared biomarker diagnostics and high awareness levels driving adoption in the maternal healthcare industry. Germany shows 8.4% growth, representing universal screening integration under EU guidelines and established prenatal care frameworks.

The UK demonstrates 8.1% growth, emphasizing NICE-endorsed PlGF tests adoption and systematic maternal health approaches. Japan exhibits 7.8% growth, focusing on maternal health program funding and healthcare infrastructure expansion. Brazil shows 7.2% growth, supported by public prenatal screening investment and expanding access to maternal healthcare services.

How does India Demonstrate Growing Market Potential with Government-Led Screening Programs?

The preeclampsia diagnostics market in India is projected to exhibit robust growth with a CAGR of 10.2% through 2035, driven by government-led maternal screening rollouts and increasing recognition of low-cost biomarker adoption as essential diagnostic components for complex prenatal care processes. The country's expanding healthcare infrastructure and growing availability of specialized maternal health capabilities are creating significant opportunities for preeclampsia testing adoption across both domestic and public health-oriented medical facilities.

Major international and domestic healthcare companies are establishing comprehensive diagnostic and distribution networks to serve the growing population of healthcare providers and maternal health facilities requiring high-performance preeclampsia screening systems across prenatal care and obstetric applications throughout India's major healthcare hubs.

The Indian government's strategic emphasis on maternal health modernization and prenatal care advancement is driving substantial investments in specialized diagnostic capabilities. This policy support, combined with the country's large domestic healthcare market and expanding maternal health requirements, creates a favorable environment for preeclampsia market development. Indian healthcare providers are increasingly focusing on high-value diagnostic technologies to improve screening capabilities, with preeclampsia testing representing a key component in this maternal healthcare transformation.

• Government initiatives supporting maternal health development and prenatal care modernization are driving demand for high-efficiency preeclampsia diagnostics throughout major healthcare and obstetric centers, including Mumbai, Delhi, and Bangalore regions.
• Screening capacity expansion and diagnostic system development are supporting appropriate utilization of preeclampsia testing among healthcare providers and maternal health facilities nationwide, with growth in hospital operations and prenatal care services.

How does China Demonstrate Exceptional Market Potential amid Hospital Digitization?

The preeclampsia diagnostics market in China is expanding at a CAGR of 9.8%, supported by regulatory approval of rapid urine tests, growing hospital digitization, and developing diagnostic market presence across the country's major healthcare clusters. The country's large maternal healthcare sector and increasing recognition of advanced preeclampsia testing systems are driving demand for effective high-efficiency diagnostic solutions in both prenatal care and obstetric applications.

International healthcare companies and domestic providers are establishing comprehensive distribution channels to serve the growing demand for quality preeclampsia diagnostics while supporting the country's position as an emerging maternal health technology market. China's maternal healthcare sector continues to benefit from favorable prenatal care policies, expanding diagnostic capabilities, and cost-competitive laboratory infrastructure development.

The country's focus on becoming a global healthcare technology hub is driving investments in specialized preeclampsia testing technology and maternal health infrastructure. This development is particularly important for preeclampsia diagnostics applications, as healthcare providers seek reliable domestic sources for critical biomarker technologies to reduce import dependency and improve supply chain security.

• Rising awareness about early detection options and improving maternal healthcare capabilities are creating opportunities for specialized preeclampsia diagnostics across prenatal care and obstetric settings in major hubs like Beijing, Shanghai, and Guangzhou.
• Growing healthcare infrastructure development and technology adoption are supporting increased access to high-efficiency preeclampsia testing among organizations requiring comprehensive diagnostic capabilities, particularly in maternal health and prenatal care organizations.

How does the USA maintain Clinical Leadership in the Preeclampsia Domain?

The USA's advanced maternal healthcare market demonstrates sophisticated diagnostic deployment with documented preeclampsia testing effectiveness in hospital departments and prenatal care centers through integration with existing healthcare systems and obstetric infrastructure.

The country leverages clinical expertise in diagnostic technology and healthcare systems integration to maintain an 8.9% CAGR through 2035. Medical centers, including major metropolitan areas, showcase premium installations where preeclampsia testing systems integrate with comprehensive healthcare information systems and laboratory platforms to optimize diagnostic accuracy and operational workflow effectiveness.

American healthcare providers prioritize system reliability and clinical compliance in diagnostic development, creating demand for premium systems with advanced features, including FDA clearance validation and integration with US healthcare standards. The market benefits from established maternal healthcare industry infrastructure and a willingness to invest in advanced preeclampsia testing technologies that provide long-term operational benefits and compliance with clinical regulations. High awareness levels regarding preeclampsia risks and complications drive proactive screening adoption among both healthcare providers and expectant mothers.

What is the Outlook for the Preeclampsia Market in Germany?

Germany's market expansion benefits from diverse maternal healthcare demand, including prenatal care modernization in Berlin and Munich, diagnostic development programs, and government healthcare programs that increasingly incorporate preeclampsia screening solutions for maternal health enhancement applications.

The country maintains an 8.4% CAGR through 2035, driven by universal screening integration under EU guidelines and increasing adoption of biomarker testing benefits, including superior diagnostic capabilities and reduced pregnancy complication complexity.

Market dynamics focus on cost-effective preeclampsia diagnostics that balance advanced testing features with affordability considerations important to German healthcare operators. Growing maternal healthcare infrastructure creates demand for modern diagnostic systems in new prenatal care facilities and obstetric equipment modernization projects.

Strategic Market Considerations:

• Maternal healthcare and prenatal care segments leading growth with focus on screening enhancement and operational efficiency applications
• Regional clinical requirements are driving a diverse product portfolio from basic preeclampsia tests to advanced biomarker platforms
• Import dependency challenges offset by potential local development partnerships with international diagnostic manufacturers
• Government maternal health initiatives beginning to influence procurement standards and prenatal care requirements

What are the Prospects for the Preeclampsia Market’s Expansion in the UK?

UK demonstrates strong market development with an 8.1% CAGR through 2035, distinguished by healthcare operators' preference for NICE-endorsed PlGF tests adoption that integrate seamlessly with existing prenatal care protocols and provide reliable long-term operation in specialized maternal health applications.

The market prioritizes evidence-based features, including validated biomarker algorithms, quality assurance, and integration with comprehensive NHS healthcare platforms that reflect British clinical expectations for diagnostic rigor and operational excellence.

British healthcare providers focus on system reliability and clinical validity in preeclampsia screening development, creating demand for endorsed systems with advanced features including automated quality monitoring and comprehensive maternal health support. The market benefits from established maternal healthcare research infrastructure and investment in diagnostic technology that provides long-term clinical benefits.

Strategic Market Indicators:

• Clinical focus on NICE-endorsed systems with validated biomarker algorithms and high-reliability capabilities
• Integration requirements with existing NHS information systems and maternal health management platforms
• Emphasis on preeclampsia testing reliability and long-term performance in prenatal care applications

How will Precision and Program Funding in Japan Widen Prospects for Preeclampsia Diagnostics in Japan?

Japan demonstrates steady market development with a 7.8% CAGR through 2035, distinguished by healthcare operators' preference for high-quality preeclampsia diagnostics that integrate seamlessly with existing maternal health equipment and provide reliable long-term operation in specialized prenatal care applications. The market prioritizes advanced features, including precision biomarker algorithms, quality validation, and integration with comprehensive maternal healthcare platforms that reflect Japanese clinical expectations for technological sophistication and operational excellence.

Japanese healthcare providers focus on system reliability and precision in preeclampsia screening development, creating demand for premium systems with advanced features including automated quality monitoring and comprehensive maternal health support. The market benefits from established maternal healthcare research infrastructure and investment in diagnostic technology that provides long-term clinical benefits through government-funded maternal health programs.

Strategic Market Indicators:

• Premium focus on precision systems with advanced biomarker algorithms and high-reliability capabilities
• Integration requirements with existing maternal healthcare information systems and prenatal care management platforms
• Emphasis on preeclampsia testing reliability and long-term performance in obstetric applications

What is the Preeclampsia Market’s Forecast for Brazil?

Brazil demonstrates developing market expansion with a 7.2% CAGR through 2035, driven by public prenatal screening investment and expanding maternal healthcare infrastructure across the country's major urban centers. The government's commitment to improving maternal mortality rates through enhanced screening programs is creating opportunities for preeclampsia diagnostic adoption in public health facilities. The market benefits from growing awareness of pregnancy complications and the clinical benefits of early detection in reducing adverse maternal and fetal outcomes.

Brazilian healthcare providers are increasingly incorporating preeclampsia screening into routine prenatal care protocols, supported by public health initiatives and expanding laboratory capacity. The focus on cost-effective diagnostic solutions that can serve large patient populations makes Brazil an attractive market for companies offering scalable testing platforms.

Europe Market Split by Country

The preeclampsia market in Europe is projected to grow from USD 544.0 million in 2025 to USD 1,272.0 million by 2035, registering a CAGR of 8.9% over the forecast period. Germany is expected to maintain its leadership position with a 24.5% market share in 2025, rising to 25.2% by 2035, supported by its advanced maternal healthcare infrastructure, precision diagnostic capabilities, and strong prenatal care presence throughout major medical regions.

The UK follows with a 19.0% share in 2025, projected to reach 19.8% by 2035, driven by NICE-endorsed screening protocols, maternal health innovation integration, and expanding specialty obstetric networks serving both domestic and international markets. France holds a 15.5% share in 2025, expected to increase to 16.1% by 2035, supported by maternal healthcare infrastructure expansion and growing adoption of high-efficiency preeclampsia diagnostics.

Italy commands a 12.0% share in 2025, projected to reach 12.5% by 2035, while Spain accounts for 10.5% in 2025, expected to reach 10.9% by 2035. The rest of Europe region, including Nordic countries, Eastern Europe, and smaller Western European markets, is anticipated to hold 18.5% in 2025, declining slightly to 15.5% by 2035, attributed to market consolidation toward larger core markets with established maternal healthcare and prenatal care capabilities.

Competitive Landscape of the Preeclampsia Market

The preeclampsia market is characterized by competition among established diagnostic manufacturers, specialty biomarker companies, and healthcare technology suppliers focused on delivering high-efficiency, consistent, and reliable preeclampsia testing systems.

Companies are investing in biomarker technology advancement, performance control enhancement, strategic partnerships, and customer technical support to deliver effective, efficient, and reliable preeclampsia diagnostics that meet stringent healthcare and maternal health requirements. Diagnostic optimization, validation protocols, and supply chain strategies are central to strengthening product portfolios and market presence.

Roche leads the market with a 16.0% share, providing comprehensive high-efficiency preeclampsia diagnostic offerings with a focus on performance consistency and testing reliability for maternal healthcare applications. The company's Elecsys sFlt-1/PlGF ratio receiving FDA 510(k) clearance for preeclampsia risk stratification in 2025 strengthens its competitive position.

Revvity (PerkinElmer) provides specialized biomarker testing systems with emphasis on maternal health applications and comprehensive technical support services. Thermo Fisher Scientific focuses on advanced diagnostic technologies and customized healthcare solutions for preeclampsia testing systems serving global markets through its partnership with Trinity Biotech on the FDA-cleared PreClara Ratio test.

Trinity Biotech delivers established diagnostic systems with strong performance control systems and customer service capabilities, highlighted by its 2025 commercial launch of the PreClara Ratio sFlt-1/PlGF test for US hospitals. Sera Prognostics operates with a focus on bringing innovative biomarker technologies to specialized maternal health applications and emerging markets.

Siemens Healthineers provides comprehensive diagnostic system portfolios, including advanced preeclampsia testing, across multiple healthcare applications and maternal health processes. Bayer AG specializes in customized diagnostic solutions and performance management systems for healthcare systems with emphasis on clinical compliance.

Quidel Corp provides reliable supply chain solutions and technical expertise to enhance market accessibility and customer access to essential preeclampsia diagnostics. Eurofins NTD Genetics, Labcorp, and mProbe Inc. contribute to market development through specialized testing capabilities and expanding service networks.

Recent market developments demonstrate the accelerating pace of innovation and regulatory approval. Mirvie announced in 2025 a non-invasive molecular blood test for early preeclampsia risk prediction between 17.5 and 22 weeks gestation, representing the next generation of screening technology. These developments reflect the industry's commitment to improving early detection capabilities, expanding access to validated diagnostics, and supporting comprehensive maternal health screening programs worldwide.

Key Players in the Preeclampsia Market

• Roche
• Revvity (PerkinElmer)
• Thermo Fisher Scientific
• Trinity Biotech
• Sera Prognostics
• Siemens Healthineers
• Bayer AG
• Quidel Corp
• Eurofins NTD Genetics
• Labcorp
• mProbe Inc.
• Mirvie
• Quest Diagnostics
• Abbott Laboratories
• Bio-Rad Laboratories

Scope of the Report

Items	Values
Quantitative Units (2025)	USD 1.36 billion
Test Type	Blood Tests, Urinalysis
Application	Universal Screening, Targeted Testing, Monitoring & Recurrence
End Use	Diagnostic Centers, Hospitals, Specialty Clinics, Others
Regions Covered	Asia Pacific, North America, Europe, Latin America, Middle East & Africa
Countries Covered	China, USA, Germany, Japan, India, UK, Brazil and 40+ countries
Key Companies Profiled	Roche, Revvity (PerkinElmer), Thermo Fisher Scientific, Trinity Biotech, Sera Prognostics, Siemens Healthineers, Bayer AG, Quidel Corp, Eurofins NTD Genetics, Labcorp, and mProbe Inc.
Additional Attributes	Dollar sales by test type and application, regional demand trends, competitive landscape, healthcare provider preferences for specific preeclampsia diagnostics, integration with specialty maternal health supply chains, innovations in biomarker technologies, performance monitoring, and diagnostic optimization

Preeclampsia Market by Segments

• Test Type :

  • Blood Tests
    • sFlt-1/PlGF ratio assays
    • Other blood biomarkers
  • Urinalysis

• Application :

  • Universal Screening
    • First-trimester screening
    • Other screening protocols
  • Targeted Testing
  • Monitoring & Recurrence

• End Use :

  • Diagnostic Centers
    • Urban labs
    • Other diagnostic facilities
  • Hospitals
  • Specialty Clinics
  • Others

• Region :

  • Asia Pacific

    • China
    • India
    • Japan
    • South Korea
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia Pacific

  • North America

    • USA
    • Canada
    • Mexico

  • Europe

    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Nordic
    • BENELUX
    • Rest of Europe

  • Latin America

    • Brazil
    • Argentina
    • Chile
    • Rest of Latin America

  • Middle East & Africa

    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Other African Countries
    • Rest of Middle East & Africa